{"name":"EyePoint Pharmaceuticals, Inc.","slug":"eyepoint-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AKB-9778 4%","genericName":"AKB-9778 4%","slug":"akb-9778-4","indication":"Other","status":"phase_2"},{"name":"Dexycu","genericName":"Dexycu","slug":"dexycu","indication":"Other","status":"marketed"},{"name":"AKB-9778","genericName":"AKB-9778","slug":"akb-9778","indication":"Other","status":"phase_2"},{"name":"Prednisolone Acetate Ophthalmic","genericName":"Prednisolone Acetate Ophthalmic","slug":"prednisolone-acetate-ophthalmic","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EYP-1901","genericName":"EYP-1901","slug":"eyp-1901","indication":"Dry eye disease","status":"phase_3"}]}],"pipeline":[{"name":"AKB-9778 4%","genericName":"AKB-9778 4%","slug":"akb-9778-4","phase":"phase_2","mechanism":"AKB-9778 is a Tie2 receptor tyrosine kinase activator that stabilizes blood vessels and reduces vascular leakage in the retina.","indications":[],"catalyst":""},{"name":"Dexycu","genericName":"Dexycu","slug":"dexycu","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AKB-9778","genericName":"AKB-9778","slug":"akb-9778","phase":"phase_2","mechanism":"AKB-9778 inhibits VE-PTP (vascular endothelial protein tyrosine phosphatase), enhancing Tie2 receptor signaling to stabilize blood vessels.","indications":[],"catalyst":""},{"name":"EYP-1901","genericName":"EYP-1901","slug":"eyp-1901","phase":"phase_3","mechanism":"EYP-1901 is a sustained-release corticosteroid implant designed to deliver anti-inflammatory therapy directly to the eye.","indications":["Dry eye disease","Anterior uveitis"],"catalyst":""},{"name":"Prednisolone Acetate Ophthalmic","genericName":"Prednisolone Acetate Ophthalmic","slug":"prednisolone-acetate-ophthalmic","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPa1ZvVGVNQWtBV1FmLU5vWVAzTF9wZnVzZW5qcDFLQzNvN29WMDZFT0pQd29WRENZby1TZUFPZndRb1Q2Q1VvLV9LanpuZkgtVEZqVk10dndkTVRXS2JKTnpFRUF1cW5sSHdyOW1jUWtfbE81QnNUR0l2N1AxeENmRm5DczU0U0tRblZWSks4Y3dGeE5YWUpaa1M2R1o0cUtScXZDS28tbHBuOElLSFpQcEJMN0RBMm9j?oc=5","date":"2026-03-23","type":"pipeline","source":"Fierce Pharma","summary":"EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race - Fierce Pharma","headline":"EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNU21XNUprNzNEeDVINC12Wk1oaG1PZGZINEtycllpVVoxRk5MSnkwWGlSQUM2UzQ4bGw0Tzdvc0cxOWRsN256VnJsbEZxYkhxRzJtODlieG12YktjQ0FucmNHQVUzeVdQblRVejZGVHdCSWx5M2dtNWdOY2oxek4yQWVpcnVQS0h0aGd5Q0c4c2NJWkFuelRXSFpHRTdHcXBvNkphcUREaERRWWNNUlh1SGVENA?oc=5","date":"2026-03-03","type":"trial","source":"Investing.com","summary":"Eyepoint Pharma earnings up next as pivotal trial data looms - Investing.com","headline":"Eyepoint Pharma earnings up next as pivotal trial data looms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxQbE9kSmQtYlZKNzJyV1R0MmRJc2ZZa0NWdmdLaDY5czhSdG5lc2VBNENYSkxYRzRtSE5saS05QUdBV0traWUxZmxIZEJLbldIZ0UyelFBT2JsOUdoRmdBUTVMOWkxdVRxTUN1Z1hQUGRFX2EyeGlxM0R4b3FtUzAzQzhaVWZtVnlhem1pOWtkd0FTaFR4SkVRY0VfdWN5czlpaGVIeEw2TmJ5c3RERmFRTE8yemY3LUJuN2h5cThRQWNJOWF1a2dKdXRYejB6VlNNVkVwaVA1Z2p5YllISEw3VGY4SXFmS3dEdzhSdjFwUjdMSjlWQU9qR3hzcnJ5elhNVjZORlBzdkg4eWR4Y3VOcG9xRDgxcjZ0Ul9WclFYSnJuT2hCcTlsTEhVUG9GZF9jZ1M2OG1lV1ZmRXBEZ1E?oc=5","date":"2026-01-09","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Viking Therapeutics (VKTX) and ANI Pharmaceuticals (ANIP) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Viking Therapeutics (VKTX) and ANI Pha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOcVpBdXhvamRtNUJjdGJzNktGMFdnV1NaTkZHeDZhVzJYRFlRRW5CNjNXcVJDM2h2blNIaVc3V3BoV0MzQmU3cTZzZThYdmhpcjFEaXlaNXpWT2dWUWF2SGxRcUloSllzSWREcUJNMmxVZnlKMmVxaTdYTnZWZ0psdFJIUFc1N1g5bjVWWVFxekY?oc=5","date":"2025-11-06","type":"earnings","source":"Yahoo Finance","summary":"EyePoint Pharmaceuticals (EYPT): Forecast 61.3% Revenue Growth Tests Premium Valuation, Ongoing Losses - Yahoo Finance","headline":"EyePoint Pharmaceuticals (EYPT): Forecast 61.3% Revenue Growth Tests Premium Valuation, Ongoing Losses","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOTHJZSWptVndZR3hBUzIxRGo2WEhmTFFDYjRWby1qUUE3VWR3SWxNbTVfVnlTaW11eFlyTkE0SnRKUC1HbnBSSVJOUGFQWjREM1k3ejNjS2dfdWNtU0F1QndfdEtUTHlsZGczdjQ2cjNtbUFtdl93ZkpJeTctcjFHT29nMFBZVHN1TUdKc2YxWUpSM1hJUS04VTBlVHcwdUQxRkxnRjJONHVLRGVNbFMzM3BPdUhfY1Jw?oc=5","date":"2025-10-14","type":"pipeline","source":"GlobeNewswire","summary":"EyePoint Announces Pricing of Public Offering - GlobeNewswire","headline":"EyePoint Announces Pricing of Public Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQOWJ1WnVvVjFBYUpyWXVmNkxjVDZoVHVHNmZ6OHc2eFRXdkxjYkMxaWVRbFpEX1NsOXdTM3h2eXZrcVp4RnpXc1JzNEdnX1VLRE5mRGROekNZbUVYSG03MGZKZTV2OGcwNXhCY1d2RHQ5WWtiUExINzVYS0hnLVZQWFlLT2dqbkhwR2lyWHBESi01eHZ3OFFzbGZVcjR6cHNwTEE3Ym1ZWXJuRnY0MDJ4UmVraw?oc=5","date":"2025-01-15","type":"pipeline","source":"Optometry Times","summary":"EyePoint Pharmaceuticals provides company updates, 2025 milestones for Duravyu - Optometry Times","headline":"EyePoint Pharmaceuticals provides company updates, 2025 milestones for Duravyu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9GeG5RdG91TDdEWG9Qb3BiYUpXdzQtZjZDdVhSUWNIdW1RNTF2Y0FrVTZsN1JRVUVWbG82MU1mYmZqUVJIa2dMc1JFQ19fMVNEWENRSHNkNEJpUTI3TUNTVHZjS19EV3VFaGE3OXlzcnNVYmItS3FxY09R?oc=5","date":"2024-06-29","type":"pipeline","source":"The Pharma Letter","summary":"EyePoint Pharmaceuticals | Biotechnology | The Pharmaletter - The Pharma Letter","headline":"EyePoint Pharmaceuticals | Biotechnology | The Pharmaletter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPMzc0dEM5Rjd6cml2dVlJODdqZ05tb3RhTmk1V3FqMmJHdGc2Z3VZazZVVmdYenhrWFVwODZmVXdlRlpFaUYyNGFpSnlvZzBJZTR4SjdQdmpKU01uT2pTbDVrdW1uNk1Sekcwb2ZQU085NHZlVlVVV0VFd1YtdVRHQ2UtS3pJUTdTbXNYcUhMekpOTElSd0U0VHlNUHFhdzQ0aEhkUVFPb3piZTdF?oc=5","date":"2024-03-12","type":"pipeline","source":"Pharmaceutical Technology","summary":"EyePoint Pharmaceuticals’s cGMP Manufacturing Facility, USA - Pharmaceutical Technology","headline":"EyePoint Pharmaceuticals’s cGMP Manufacturing Facility, USA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQZHRsYVQ3czZnMHN5ZFRjSjdjZ3htWm1ZN284Y2xPaC1JRF92VXBlMzBjeDlPZFNHX1pTbUxGV1Z3VDRvWUdkdWJBUnNmYnlhaTk4X0R2N2ZYZTlGbjRCNWRvVWdfYTd6d3lHZnZqRlEwNXpnSVAtNDg3YVJDbV9QWHlTNDlidzRablkxN0lBcV82Mm9UWmFrSmlwVXY3U2JqY0l0VkliMXFkS0hCZXBObjVyUjdranQ3LW9mNWdpeUlBLUFvQVE?oc=5","date":"2024-03-07","type":"pipeline","source":"Alkermes","summary":"Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors - Alkermes","headline":"Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNbG9iMDVaZVRBMFlHZjRKcUJ1YUlObUxWWTdldThvRnhnNUY0V2QtRXhqQV9mY0FkV1VtUFBnZ1dxSFVlUnJ2dFh6YVcyUVFESWl5VG13UENyREtRWmNMc2hjT0RrZV8yNVl2VXdienpuSXJkUTg2cWJxd1dXM0ptdjdpSjZmTnN0aHc?oc=5","date":"2023-12-04","type":"pipeline","source":"Seeking Alpha","summary":"EyePoint Pharma stock surges after wet AMD success - Seeking Alpha","headline":"EyePoint Pharma stock surges after wet AMD success","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQNmFfWkdsUlIyaXBabEhudEZDNHVkOFR6RHBZajk1aEh1cUotU1dmUjMwMGdJbS1LYzRSYms1b1oxUVY3MDU1RjZ0dXVocFFjT0ZoVHc1VUxOQlozTzFJMWVaWElVU2RpOFRtdkx2VEdORTd0MVJLVVdabzNmSGR1N0owbFZGUUJwLUU0Z0ZSel90blhkc25tMVBKYXJKbzlxcXBmdmlQYmhOSFpSSDNKejk1bUY?oc=5","date":"2023-01-23","type":"pipeline","source":"Contract Pharma","summary":"EyePoint Pharmaceuticals to Build GMP Mfg. Facility in Northbridge, MA - Contract Pharma","headline":"EyePoint Pharmaceuticals to Build GMP Mfg. Facility in Northbridge, MA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOSlROZ1o3dFRxTWt1MUFsa1FtWkJBRl9STTdQQXZwOEozYjZiZVNsb2xJTC14VS1tamtGZjhoY0haR0FleFl6OV9hQkI5QlZEeG9sLWlsNG50dTdmdXZuYm9lSmhlVnlkRU9XSTBRdFZQR1lPWlY4bml6RDB4NFlTbVVYa0o0TWI2SjRUZ0p5MVF6RU9Xcnczbm9VazdGVTFNN0VtTUVqUWg4ZTFmS2Z4NkJSaWpTNzRoa2FydXl3ZFM0QU11RE1pMmY1Ul91N0RoMTNDeWgwbHlBaWlWcFR3WDM1blo5bjhZekNPNTZYSnZtWktmZTJfRUJJVVJJVWFJZG9zTU1jdER4MEtFd19NY3JWaUZ4X1d4YTlGMTJJYmE4SFk?oc=5","date":"2022-08-01","type":"trial","source":"PR Newswire","summary":"EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD - PR Newswire","headline":"EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":2,"marketed":2,"phase_3":1},"enrichmentLevel":2,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}